Insider Selling: Scholar Rock (NASDAQ:SRRK) General Counsel Sells $445,757.40 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) General Counsel Junlin Ho sold 9,580 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total value of $445,757.40. Following the transaction, the general counsel owned 241,545 shares in the company, valued at approximately $11,239,088.85. This trade represents a 3.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Junlin Ho also recently made the following trade(s):

• On Friday, January 16th, Junlin Ho sold 8,016 shares of Scholar Rock stock. The stock was sold at an average price of $44.48, for a total value of $356,551.68.

Scholar Rock Stock Up 0.6%

SRRK stock opened at $48.00 on Friday. Scholar Rock Holding Corporation has a 52 week low of $22.71 and a 52 week high of $49.82. The business has a 50-day simple moving average of $45.16 and a 200 day simple moving average of $38.38. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41. The company has a market cap of $4.90 billion, a PE ratio of -15.24 and a beta of 0.67.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research report on Thursday, December 11th. UBS Group started coverage on Scholar Rock in a report on Wednesday, January 7th. They set a “buy” rating and a $60.00 price target for the company. Barclays raised their price objective on Scholar Rock from $45.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. JPMorgan Chase & Co. boosted their target price on Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. Finally, Citigroup initiated coverage on shares of Scholar Rock in a report on Friday, January 9th. They issued a “buy” rating and a $55.00 target price for the company. Four research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $51.14.

Hedge Funds Weigh In On Scholar Rock

Large investors have recently bought and sold shares of the company. IFP Advisors Inc boosted its stake in shares of Scholar Rock by 294.1% during the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after purchasing an additional 450 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Scholar Rock during the 4th quarter worth approximately $30,000. Summit Securities Group LLC acquired a new stake in Scholar Rock during the 4th quarter worth approximately $31,000. Ramirez Asset Management Inc. bought a new stake in Scholar Rock during the 3rd quarter worth approximately $37,000. Finally, EverSource Wealth Advisors LLC increased its position in Scholar Rock by 151.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after acquiring an additional 525 shares during the period. 91.08% of the stock is currently owned by institutional investors.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).